Suchen
Nervgen Pharma Ord Shs
NGENZur Watchlist hinzufügen
2.120USD
+0.030+1.44%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
171.78MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Nervgen Pharma Ord Shs Unternehmen
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
Nervgen Pharma Ord Shs Informationen
BörsenkürzelNGEN
Name des UnternehmensNervGen Pharma Corp
IPO-datumMar 13, 2019
CEORogers (Adam H)
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
Geschäftsjahresende- -
AddresseSuite 1703 - 595 Burrard Street
StadtVANCOUVER
BörseNASDAQ OMX - NASDAQ BASIC
LandCanada
PostleitzahlV7X 1J1
Telefon16047225361
Websitehttps://www.nervgen.com/
BörsenkürzelNGEN
IPO-datumMar 13, 2019
CEORogers (Adam H)
Führungskräfte von Nervgen Pharma Ord Shs
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Randall E. Kaye, M.D.
Dr. Randall E. Kaye, M.D.
Independent Director
Independent Director
160.00K
-31.25%
Ms. Krista L. Mckerracher
Ms. Krista L. Mckerracher
Independent Director
Independent Director
27.76K
-54.04%
,
,
--
--
Mr. Brian Eric Bayley
Mr. Brian Eric Bayley
Independent Director
Independent Director
--
--
Dr. Harold Martin Punnett
Dr. Harold Martin Punnett
Independent Director
Independent Director
--
--
Mr. William J. (Bill) Adams
Mr. William J. (Bill) Adams
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Dr. Daniel D. (Dan) Mikol, M.D., Ph.D
Dr. Daniel D. (Dan) Mikol, M.D., Ph.D
Chief Medical Officer
Chief Medical Officer
--
--
Mr. John Craig Thompson
Mr. John Craig Thompson
Independent Director
Independent Director
--
--
Dr. Adam H. Rogers
Dr. Adam H. Rogers
Chairman of the Board, Interim Chief Executive Officer
Chairman of the Board, Interim Chief Executive Officer
--
--
Mr. Gianni (John) Ruffolo
Mr. Gianni (John) Ruffolo
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Randall E. Kaye, M.D.
Dr. Randall E. Kaye, M.D.
Independent Director
Independent Director
160.00K
-31.25%
Ms. Krista L. Mckerracher
Ms. Krista L. Mckerracher
Independent Director
Independent Director
27.76K
-54.04%
,
,
--
--
Mr. Brian Eric Bayley
Mr. Brian Eric Bayley
Independent Director
Independent Director
--
--
Dr. Harold Martin Punnett
Dr. Harold Martin Punnett
Independent Director
Independent Director
--
--
Mr. William J. (Bill) Adams
Mr. William J. (Bill) Adams
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Nervgen Pharma Ord Shs?
Die fünf größten Anteilseigner von Nervgen Pharma Ord Shs sind: Dr. Randall E. Kaye, M.D.
Wie viele Institutionen halten Anteile an Nervgen Pharma Ord Shs (NGEN)?
Mit Stand vom 2026Q1 halten 17 Institutionen Anteile an Nervgen Pharma Ord Shs, mit einem Gesamtmarktwert von etwa 350.93K, was 0.44% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 303132.00 gestiegen.